Effect of oral vancomycin dose on outcomes in patients with Clostridioides difficile infection
| العنوان: | Effect of oral vancomycin dose on outcomes in patients with Clostridioides difficile infection |
|---|---|
| المؤلفون: | Kristina Roddy, Odirichukwu O. Duru, Gregory M. Novak, Monique R Bidell, J. Nicholas O'Donnell, Benjamin R. Bratek, Gurkirat Singh, Colby Mitchell |
| المصدر: | International journal of antimicrobial agents. 57(4) |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Microbiology (medical), Male, medicine.medical_specialty, Fulminant, 030106 microbiology, Administration, Oral, Disease, 03 medical and health sciences, 0302 clinical medicine, Recurrence, Vancomycin, Internal medicine, Medicine, Humans, Pharmacology (medical), In patient, 030212 general & internal medicine, Dosing, Oral vancomycin, Enterocolitis, Pseudomembranous, Aged, Retrospective Studies, business.industry, Clostridioides difficile, Standard of Care, General Medicine, Guideline, Middle Aged, Anti-Bacterial Agents, Infectious Diseases, Treatment Outcome, Female, business, Clostridioides, medicine.drug |
| الوصف: | Clostridioides difficile infection (CDI) is a significant cause of morbidity and mortality. Oral vancomycin is a cornerstone of CDI treatment, but dosing strategies in clinical practice may differ from guideline recommendations. This study aimed to determine differences in outcomes between patients treated with standard (125 mg QID) and high-dose (≥250 mg QID) oral vancomycin. This dual-centre study evaluated adult patients admitted between January 2013 and July 2017. Patients were included in the study if they had a positive C. difficile toxin PCR, symptomatic infection and received ≥48 h of oral vancomycin. Disease severity was characterised using a variety of classifiers, including guideline definitions. The primary outcome was 90-day CDI recurrence; secondary outcomes included clinical failure, in-hospital mortality and 90-day re-admission. Inverse probability of treatment weighting (IPTW) was conducted to balance differences between groups. A total of 535 patients were included; 261 received standard and 274 received high-dose vancomycin. Baseline demographics were similar between groups, except that patients receiving high-dose vancomycin were more likely to have more severe disease and to be admitted to the ICU. Few patients had fulminant disease (14.4%). No significant differences in recurrence (OR, 1.52, 95% CI 0.82-2.84), clinical failure (OR, 0.64, 95% CI 0.328-1.26), mortality (OR, 1.44, 95% CI 0.78-2.66) or re-admission (OR, 1.03, 95% CI 0.70-1.51) were identified between patients receiving standard and high-dose vancomycin in the IPTW analyses. No differences in recurrence, mortality or re-admission were identified between standard and high-dose vancomycin for the treatment of CDI not requiring surgery. |
| تدمد: | 1872-7913 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8df36554b6fc5370777f06e4038fcee https://pubmed.ncbi.nlm.nih.gov/33621602 |
| Rights: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....d8df36554b6fc5370777f06e4038fcee |
| قاعدة البيانات: | OpenAIRE |
| ResultId |
1 |
|---|---|
| Header |
edsair OpenAIRE edsair.doi.dedup.....d8df36554b6fc5370777f06e4038fcee 845 3 unknown 844.710266113281 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d8df36554b6fc5370777f06e4038fcee&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8df36554b6fc5370777f06e4038fcee# [Name] => EDS - OpenAIRE [Category] => fullText [Text] => View record in OpenAIRE [MouseOverText] => View record in OpenAIRE ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Effect of oral vancomycin dose on outcomes in patients with Clostridioides difficile infection
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Kristina+Roddy%22">Kristina Roddy</searchLink><br /><searchLink fieldCode="AR" term="%22Odirichukwu+O%2E+Duru%22">Odirichukwu O. Duru</searchLink><br /><searchLink fieldCode="AR" term="%22Gregory+M%2E+Novak%22">Gregory M. Novak</searchLink><br /><searchLink fieldCode="AR" term="%22Monique+R+Bidell%22">Monique R Bidell</searchLink><br /><searchLink fieldCode="AR" term="%22J%2E+Nicholas+O'Donnell%22">J. Nicholas O'Donnell</searchLink><br /><searchLink fieldCode="AR" term="%22Benjamin+R%2E+Bratek%22">Benjamin R. Bratek</searchLink><br /><searchLink fieldCode="AR" term="%22Gurkirat+Singh%22">Gurkirat Singh</searchLink><br /><searchLink fieldCode="AR" term="%22Colby+Mitchell%22">Colby Mitchell</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => <i>International journal of antimicrobial agents</i>. 57(4) ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2020 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%220301+basic+medicine%22">0301 basic medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Microbiology+%28medical%29%22">Microbiology (medical)</searchLink><br /><searchLink fieldCode="DE" term="%22Male%22">Male</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Emedical%5Fspecialty%22">medicine.medical_specialty</searchLink><br /><searchLink fieldCode="DE" term="%22Fulminant%22">Fulminant</searchLink><br /><searchLink fieldCode="DE" term="%22030106+microbiology%22">030106 microbiology</searchLink><br /><searchLink fieldCode="DE" term="%22Administration%2C+Oral%22">Administration, Oral</searchLink><br /><searchLink fieldCode="DE" term="%22Disease%22">Disease</searchLink><br /><searchLink fieldCode="DE" term="%2203+medical+and+health+sciences%22">03 medical and health sciences</searchLink><br /><searchLink fieldCode="DE" term="%220302+clinical+medicine%22">0302 clinical medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Recurrence%22">Recurrence</searchLink><br /><searchLink fieldCode="DE" term="%22Vancomycin%22">Vancomycin</searchLink><br /><searchLink fieldCode="DE" term="%22Internal+medicine%22">Internal medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Medicine%22">Medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Pharmacology+%28medical%29%22">Pharmacology (medical)</searchLink><br /><searchLink fieldCode="DE" term="%22In+patient%22">In patient</searchLink><br /><searchLink fieldCode="DE" term="%22030212+general+%26+internal+medicine%22">030212 general & internal medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Dosing%22">Dosing</searchLink><br /><searchLink fieldCode="DE" term="%22Oral+vancomycin%22">Oral vancomycin</searchLink><br /><searchLink fieldCode="DE" term="%22Enterocolitis%2C+Pseudomembranous%22">Enterocolitis, Pseudomembranous</searchLink><br /><searchLink fieldCode="DE" term="%22Aged%22">Aged</searchLink><br /><searchLink fieldCode="DE" term="%22Retrospective+Studies%22">Retrospective Studies</searchLink><br /><searchLink fieldCode="DE" term="%22business%2Eindustry%22">business.industry</searchLink><br /><searchLink fieldCode="DE" term="%22Clostridioides+difficile%22">Clostridioides difficile</searchLink><br /><searchLink fieldCode="DE" term="%22Standard+of+Care%22">Standard of Care</searchLink><br /><searchLink fieldCode="DE" term="%22General+Medicine%22">General Medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Guideline%22">Guideline</searchLink><br /><searchLink fieldCode="DE" term="%22Middle+Aged%22">Middle Aged</searchLink><br /><searchLink fieldCode="DE" term="%22Anti-Bacterial+Agents%22">Anti-Bacterial Agents</searchLink><br /><searchLink fieldCode="DE" term="%22Infectious+Diseases%22">Infectious Diseases</searchLink><br /><searchLink fieldCode="DE" term="%22Treatment+Outcome%22">Treatment Outcome</searchLink><br /><searchLink fieldCode="DE" term="%22Female%22">Female</searchLink><br /><searchLink fieldCode="DE" term="%22business%22">business</searchLink><br /><searchLink fieldCode="DE" term="%22Clostridioides%22">Clostridioides</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edrug%22">medicine.drug</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Clostridioides difficile infection (CDI) is a significant cause of morbidity and mortality. Oral vancomycin is a cornerstone of CDI treatment, but dosing strategies in clinical practice may differ from guideline recommendations. This study aimed to determine differences in outcomes between patients treated with standard (125 mg QID) and high-dose (≥250 mg QID) oral vancomycin. This dual-centre study evaluated adult patients admitted between January 2013 and July 2017. Patients were included in the study if they had a positive C. difficile toxin PCR, symptomatic infection and received ≥48 h of oral vancomycin. Disease severity was characterised using a variety of classifiers, including guideline definitions. The primary outcome was 90-day CDI recurrence; secondary outcomes included clinical failure, in-hospital mortality and 90-day re-admission. Inverse probability of treatment weighting (IPTW) was conducted to balance differences between groups. A total of 535 patients were included; 261 received standard and 274 received high-dose vancomycin. Baseline demographics were similar between groups, except that patients receiving high-dose vancomycin were more likely to have more severe disease and to be admitted to the ICU. Few patients had fulminant disease (14.4%). No significant differences in recurrence (OR, 1.52, 95% CI 0.82-2.84), clinical failure (OR, 0.64, 95% CI 0.328-1.26), mortality (OR, 1.44, 95% CI 0.78-2.66) or re-admission (OR, 1.03, 95% CI 0.70-1.51) were identified between patients receiving standard and high-dose vancomycin in the IPTW analyses. No differences in recurrence, mortality or re-admission were identified between standard and high-dose vancomycin for the treatment of CDI not requiring surgery. ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1872-7913 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8df36554b6fc5370777f06e4038fcee" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8df36554b6fc5370777f06e4038fcee</link><br /><link linkTarget="URL" linkTerm="https://pubmed.ncbi.nlm.nih.gov/33621602" linkWindow="_blank">https://pubmed.ncbi.nlm.nih.gov/33621602</link> ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => CLOSED ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi.dedup.....d8df36554b6fc5370777f06e4038fcee ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => Undetermined
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => 0301 basic medicine
[Type] => general
)
[1] => Array
(
[SubjectFull] => Microbiology (medical)
[Type] => general
)
[2] => Array
(
[SubjectFull] => Male
[Type] => general
)
[3] => Array
(
[SubjectFull] => medicine.medical_specialty
[Type] => general
)
[4] => Array
(
[SubjectFull] => Fulminant
[Type] => general
)
[5] => Array
(
[SubjectFull] => 030106 microbiology
[Type] => general
)
[6] => Array
(
[SubjectFull] => Administration, Oral
[Type] => general
)
[7] => Array
(
[SubjectFull] => Disease
[Type] => general
)
[8] => Array
(
[SubjectFull] => 03 medical and health sciences
[Type] => general
)
[9] => Array
(
[SubjectFull] => 0302 clinical medicine
[Type] => general
)
[10] => Array
(
[SubjectFull] => Recurrence
[Type] => general
)
[11] => Array
(
[SubjectFull] => Vancomycin
[Type] => general
)
[12] => Array
(
[SubjectFull] => Internal medicine
[Type] => general
)
[13] => Array
(
[SubjectFull] => Medicine
[Type] => general
)
[14] => Array
(
[SubjectFull] => Humans
[Type] => general
)
[15] => Array
(
[SubjectFull] => Pharmacology (medical)
[Type] => general
)
[16] => Array
(
[SubjectFull] => In patient
[Type] => general
)
[17] => Array
(
[SubjectFull] => 030212 general & internal medicine
[Type] => general
)
[18] => Array
(
[SubjectFull] => Dosing
[Type] => general
)
[19] => Array
(
[SubjectFull] => Oral vancomycin
[Type] => general
)
[20] => Array
(
[SubjectFull] => Enterocolitis, Pseudomembranous
[Type] => general
)
[21] => Array
(
[SubjectFull] => Aged
[Type] => general
)
[22] => Array
(
[SubjectFull] => Retrospective Studies
[Type] => general
)
[23] => Array
(
[SubjectFull] => business.industry
[Type] => general
)
[24] => Array
(
[SubjectFull] => Clostridioides difficile
[Type] => general
)
[25] => Array
(
[SubjectFull] => Standard of Care
[Type] => general
)
[26] => Array
(
[SubjectFull] => General Medicine
[Type] => general
)
[27] => Array
(
[SubjectFull] => Guideline
[Type] => general
)
[28] => Array
(
[SubjectFull] => Middle Aged
[Type] => general
)
[29] => Array
(
[SubjectFull] => Anti-Bacterial Agents
[Type] => general
)
[30] => Array
(
[SubjectFull] => Infectious Diseases
[Type] => general
)
[31] => Array
(
[SubjectFull] => Treatment Outcome
[Type] => general
)
[32] => Array
(
[SubjectFull] => Female
[Type] => general
)
[33] => Array
(
[SubjectFull] => business
[Type] => general
)
[34] => Array
(
[SubjectFull] => Clostridioides
[Type] => general
)
[35] => Array
(
[SubjectFull] => medicine.drug
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Effect of oral vancomycin dose on outcomes in patients with Clostridioides difficile infection
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kristina Roddy
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Odirichukwu O. Duru
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Gregory M. Novak
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Monique R Bidell
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => J. Nicholas O'Donnell
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Benjamin R. Bratek
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Gurkirat Singh
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Colby Mitchell
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 07
[M] => 08
[Type] => published
[Y] => 2020
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 18727913
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsair
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 57
)
[1] => Array
(
[Type] => issue
[Value] => 4
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => International journal of antimicrobial agents
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |